Aside from the increase ability to robustly validate targets such as SL biosynthesis, global collaboration between academia and pharmaceutical partners is expediting the process of drug discovery of new anti-protozoal drugs. For example, within the sphere of targeting SL biosynthesis in the protozoa, we have managed several projects with industrial partners, MRCT and Tres Cantos Open Lab Foundation (https://www.openlabfoundation.org, an initiative of GlaxoSmithKline), in the pursuit of identifying new compound scaffolds active against the Leishmania spp IPC synthase utilising yeast (Norcliffe et al. 2014) as a vehicle for drug discovery (Denny & Steel, 2015). The generated results and techniques could readily be translated to other disease targets. Other global initiatives include Open Innovation Drug Discovery, Eli Lilly, which is focused on cancer, cardiovascular disease, endocrine disorders, neuroscience and tuberculosis. The Centers for Therapeutic Innovation, facilitates Pfizer and academic researchers to work together in order to develop new biologics programs and WIPO Re:Search, provide participant researchers with access to patents and expertise related to drug discovery for 19 NTDs, malaria and tuberculosis (Sheridan, 2011).